Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.010 AlteredExpression disease BEFREE CF ELF contained high levels of neutrophil elastase (NE) and various serine protease inhibitors prevented CF ELF from inducing IL-8 gene expression in BET-1A cells, suggesting that NE was the dominant inducer for IL-8 production in CF ELF. 1569186 1992
CUI: C0575059
Disease: Spastic tetraparesis
Spastic tetraparesis 		0.010 Biomarker disease BEFREE Transgenic mice expressing various combinations of structural and regulatory genes of human foamy virus (HFV) develop a neurodegenerative syndrome. delta gpe transgenic mice (which express the auxiliary bel-1 and bet genes along with truncated forms of gag, pol, and env) develop a severe neurological syndrome consisting mainly of spastic tetraparesis and blindness, and show neuronal loss in the hippocampus and cerebral cortex. 9549727 1998
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE Efficacy of JQ1 in three murine models of multiple myeloma establishes the therapeutic rationale for BET bromodomain inhibition in this disease and other malignancies characterized by pathologic activation of c-Myc. 21889194 2011
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.100 AlteredExpression disease BEFREE Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia. 21949397 2011
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE Efficacy of JQ1 in three murine models of multiple myeloma establishes the therapeutic rationale for BET bromodomain inhibition in this disease and other malignancies characterized by pathologic activation of c-Myc. 21889194 2011
CUI: C0023418
Disease: leukemia
leukemia 		0.090 Biomarker disease BEFREE Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. 21964340 2011
CUI: C0023418
Disease: leukemia
leukemia 		0.090 PosttranslationalModification disease BEFREE Inhibition of BET bromodomain-promoter interactions and subsequent reduction of MYC transcript and protein levels resulted in G(1) arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines. 21949397 2011
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia 		0.060 PosttranslationalModification disease BEFREE Inhibition of BET bromodomain-promoter interactions and subsequent reduction of MYC transcript and protein levels resulted in G(1) arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines. 21949397 2011
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma 		0.020 AlteredExpression disease BEFREE Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia. 21949397 2011
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.020 PosttranslationalModification group BEFREE Inhibition of BET bromodomain-promoter interactions and subsequent reduction of MYC transcript and protein levels resulted in G(1) arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines. 21949397 2011
CUI: C0278764
Disease: Adult Burkitt Lymphoma
Adult Burkitt Lymphoma 		0.020 AlteredExpression disease BEFREE Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia. 21949397 2011
CUI: C0278879
Disease: Childhood Burkitt Lymphoma
Childhood Burkitt Lymphoma 		0.020 AlteredExpression disease BEFREE Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia. 21949397 2011
CUI: C1332206
Disease: Adult Lymphoma
Adult Lymphoma 		0.020 PosttranslationalModification disease BEFREE Inhibition of BET bromodomain-promoter interactions and subsequent reduction of MYC transcript and protein levels resulted in G(1) arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines. 21949397 2011
CUI: C1332979
Disease: Childhood Lymphoma
Childhood Lymphoma 		0.020 PosttranslationalModification disease BEFREE Inhibition of BET bromodomain-promoter interactions and subsequent reduction of MYC transcript and protein levels resulted in G(1) arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines. 21949397 2011
CUI: C0004352
Disease: Autistic Disorder
Autistic Disorder 		0.100 GeneticVariation disease GWASDB Individual common variants exert weak effects on the risk for autism spectrum disorders. 22843504 2012
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 AlteredExpression group BEFREE Inhibitors targeting the activity of BET proteins have shown potent antiproliferative effects in hematological cancers through the suppression of c-MYC and downstream target genes. 23129625 2012
CUI: C0016529
Disease: Forced expiratory volume function
Forced expiratory volume function 		0.100 GeneticVariation phenotype GWASDB Genome-wide joint meta-analysis of SNP and SNP-by-smoking interaction identifies novel loci for pulmonary function. 23284291 2012
CUI: C0035227
Disease: Respiratory Function Tests
Respiratory Function Tests 		0.100 GeneticVariation phenotype GWASCAT Genome-wide joint meta-analysis of SNP and SNP-by-smoking interaction identifies novel loci for pulmonary function. 23284291 2012
CUI: C1292769
Disease: Precursor B-cell lymphoblastic leukemia
Precursor B-cell lymphoblastic leukemia 		0.020 Biomarker disease BEFREE We investigated the therapeutic potential of JQ1, an inhibitor of the BET class of human bromodomain proteins, in B-cell acute lymphoblastic leukemia (B-ALL). 22904298 2012
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.010 Biomarker disease BEFREE BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. 22904298 2012
CUI: C1961102
Disease: Precursor Cell Lymphoblastic Leukemia Lymphoma
Precursor Cell Lymphoblastic Leukemia Lymphoma 		0.010 Biomarker disease BEFREE BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. 22904298 2012
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE We conducted a cell-based screen of genetically defined cancer cell lines using a prototypical inhibitor of BET bromodomains. 23430699 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Here we show that BET inhibitors are effective against murine primary mammary tumors, but not pulmonary metastases. 24260471 2013
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE We conducted a cell-based screen of genetically defined cancer cell lines using a prototypical inhibitor of BET bromodomains. 23430699 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.080 Biomarker phenotype BEFREE BRD4, a target of BET inhibitors, encodes two isoforms with opposite effects on tumor progression. 24260471 2013